Wall Street brokerages expect that Hologic, Inc. (NASDAQ:HOLX) will report sales of $812.58 million for the current quarter, Zacks reports. Eight analysts have made estimates for Hologic’s earnings, with the highest sales estimate coming in at $831.00 million and the lowest estimate coming in at $806.00 million. Hologic reported sales of $791.10 million in the same quarter last year, which would suggest a positive year over year growth rate of 2.7%. The company is expected to report its next earnings results after the market closes on Wednesday, January 30th.

On average, analysts expect that Hologic will report full year sales of $3.32 billion for the current year, with estimates ranging from $3.31 billion to $3.33 billion. For the next financial year, analysts forecast that the company will report sales of $3.45 billion, with estimates ranging from $3.41 billion to $3.50 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Hologic.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, November 7th. The medical equipment provider reported $0.58 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.59 by ($0.01). Hologic had a positive return on equity of 23.52% and a negative net margin of 3.46%. The firm had revenue of $813.50 million during the quarter, compared to analyst estimates of $808.63 million. During the same quarter last year, the business posted $0.50 EPS. The firm’s revenue was up 1.3% on a year-over-year basis.

A number of brokerages have weighed in on HOLX. BidaskClub raised shares of Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, October 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $48.00 price target on shares of Hologic in a report on Thursday, September 27th. Morgan Stanley cut their price target on shares of Hologic from $47.00 to $44.00 and set an “equal weight” rating on the stock in a report on Thursday, October 11th. Canaccord Genuity reaffirmed a “hold” rating and issued a $43.00 price target on shares of Hologic in a report on Thursday, November 8th. Finally, Zacks Investment Research raised shares of Hologic from a “sell” rating to a “hold” rating in a report on Tuesday, November 13th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Hologic has a consensus rating of “Hold” and an average price target of $43.33.

Shares of NASDAQ HOLX traded down $0.32 during midday trading on Friday, reaching $42.57. 41,207 shares of the stock were exchanged, compared to its average volume of 2,495,875. The company has a market cap of $12.17 billion, a PE ratio of 19.17, a price-to-earnings-growth ratio of 1.94 and a beta of 0.73. Hologic has a 52-week low of $35.10 and a 52-week high of $45.17. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.23 and a quick ratio of 0.95.

In other Hologic news, SVP Allison P. Bebo sold 6,500 shares of the company’s stock in a transaction dated Friday, November 16th. The shares were sold at an average price of $42.00, for a total value of $273,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Benjamin Jordan Cohn sold 10,000 shares of the company’s stock in a transaction dated Friday, November 30th. The shares were sold at an average price of $44.49, for a total transaction of $444,900.00. The disclosure for this sale can be found here. Insiders sold a total of 36,355 shares of company stock valued at $1,584,655 over the last three months. 0.88% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. First Hawaiian Bank lifted its stake in Hologic by 2.8% during the fourth quarter. First Hawaiian Bank now owns 9,958 shares of the medical equipment provider’s stock valued at $410,000 after buying an additional 272 shares in the last quarter. Cerebellum GP LLC purchased a new stake in Hologic during the fourth quarter valued at about $43,000. Reilly Financial Advisors LLC increased its holdings in shares of Hologic by 3.7% in the 3rd quarter. Reilly Financial Advisors LLC now owns 39,430 shares of the medical equipment provider’s stock valued at $1,616,000 after purchasing an additional 1,390 shares during the period. William Blair Investment Management LLC increased its holdings in shares of Hologic by 6.8% in the 3rd quarter. William Blair Investment Management LLC now owns 22,747 shares of the medical equipment provider’s stock valued at $932,000 after purchasing an additional 1,444 shares during the period. Finally, Prudential Financial Inc. increased its holdings in shares of Hologic by 0.5% in the 3rd quarter. Prudential Financial Inc. now owns 300,094 shares of the medical equipment provider’s stock valued at $12,298,000 after purchasing an additional 1,530 shares during the period. 91.77% of the stock is owned by institutional investors.

Hologic Company Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Story: What is a stock split?

Get a free copy of the Zacks research report on Hologic (HOLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.